|
|
|
|
|
|
|
25.02.26 - 02:15
|
STANCHART Ends Down 1%+ in London at Price 4.4% Below HK Close (AAStocks)
|
|
|
STANCHART's stock price settled 1.5% lower in London on Tuesday, ending at GBX1,789, equivalent to approximately HKD189.2, which is 4.4% lower than its closing price of HKD197.9 in Hong Kong.STANCHART unveiled its full-year results for the year ended December 2025. It recorded a reported profit before taxation at USD6.963 bi......
|
|
|
25.02.26 - 01:12
|
New York Life′s Goodwin: Affordability, Not Inflation, Is Short-Term Market Catalyst (Bloomberg)
|
|
|
Lauren Goodwin, Economist and Chief Market Strategist at New York Life Investments, joins Bloomberg Businessweek Daily to discuss the state of the US economy and inflation, Federal Reserve monetary policy, and more. Goodwin also discusses the lack of clarity around tariff inflation passthrough and the continuous fluctuation of supply chains and policy, which can then impact consumers directly and indirectly. Goodwin speaks with Carol Massar and Tim Stenovec. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.02.26 - 22:33
|
Luxfer Delivers Strong Full-Year 2025 Profitability and Cash Generation (Business Wire)
|
|
|
Portfolio focus and favorable mix drive sustained profitability, enhanced adjusted earnings growth and strong cash flow generation
Fourth Quarter 2025 Highlights*
Net Sales declined 12.3% to $90.7 million from $103.4 million, while Adjusted Net Sales1 declined 5.5%
Net Income of $0.1 million, compared to $3.3 million, and $0.12 per diluted share, with Adjusted Diluted EPS1 of $0.28 down 3.4% from $0.29
Adjusted EBITDA1 of $13.0 million, declined 5.8%
Continued execution of previously announced operational excellence initiatives, including the Riverside and Powders Saxonburg centers of excellence, expected to drive improved efficiency and generate approximately $6 million of long-term annual savings
Full Year 2025 Highlights*
Net Sales declined 1.9% to $384.6 million from $391.9 million, while Adjusted Net Sales1 increased 2.5%
Net Income of $13.1 million, or $0.48 per diluted share, compared to $18.3 million and $0.68 per diluted share, with Adjusted Diluted EPS1 of $1.11, up 12.1% from $0.99
Adjusted EBI...
|
|
|
|
|
24.02.26 - 22:03
|
Tempus Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025.
Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry)
Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hereditary volume growth of 23%
MRD volume was ~4,700 tests in the fourth quarter, up 56% quarter-over-quarter
Data and Applications revenue of $100.4 million in the fourth quarter, representing 25.1% year-over-year growth, with Insights (data licensing) growing 69.5%, excluding the impact of the AstraZeneca warrant in Q4 of 2024
Ended the year with over $1.1 billion in Total Remaining Contract Value and 126% Net Revenue Retention
$759.7 million in cash and marketable securities as of December 31, 2025
Revenue guidance o...
|
|
|
|
|
|
|
|
|
|
Alle News zu Großbritannien 10712.312 +0.03% (FTSE 100 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
